Advertisements



We are Sorry, This Page doesn't Exist


Analyst: Sarepta"s DMD Gene Therapy Results "Dramatic And Far Exceeding Expectations"

Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported some encouragi.....»»

Category: blogSource: benzinga5 hr. 14 min. ago

Sarepta shares rocket 50% on promising early results for DMD gene therapy

Earlier this year, Sarepta’s CEO bet the company would be known best for its genetic medicine advances. The latest results suggest he could be right......»»

Category: topSource: marketwatch6 hr. 59 min. ago

Sarepta shares skyrocket 66% on early positive results for DMD gene therapy

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatch7 hr. 14 min. ago

Sarepta Hits Record High As Duchenne Muscular Dystrophy Gene Therapy Yields Positive Results In Early-Stage Study

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares, halted shortly before Tuesday's open, opened higher by more than 50 percent. read more.....»»

Category: blogSource: benzinga7 hr. 29 min. ago

Baird analyst calls Sarepta gene therapy data a "game changer"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall8 hr. 44 min. ago

Sarepta jumps 53% to $161.01 after gene therapy data top expectations

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall8 hr. 44 min. ago

Solid Biosciences rallies 17% to $34.44 following Sarepta gene therapy data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall8 hr. 44 min. ago

Sarepta: DMD gene therapy shows 38.2% of micro-dystrophin in Phase 1/2a study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall8 hr. 44 min. ago

Sarepta DMD gene therapy shows 38% of micro-dystrophin in Phase 1/2a study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall8 hr. 44 min. ago

Sarepta gene therapy produced "jaw-dropping" protein increases, STAT says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall8 hr. 44 min. ago

Sarepta shares rocket 55% on positive early results for DMD gene therapy

Sarepta Therapeutics Inc. shares rocketed 55.6% in extremely heavy Tuesday morning trade after the company reported positive early results from a phase 1/2a gene therapy clinical trial for three patients with the rare.....»»

Category: topSource: marketwatch8 hr. 44 min. ago

Caladrius receives FDA RMAT designation for CD34+ cell therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall10 hr. 59 min. ago

Nationwide Children"s gene therapy inventors hired away by pharma giants – why that"s good for recruitment

Two lead inventors of three of the four gene therapy treatments that Nationwide Children's Hospital has licensed to spinoffs have been hired away since fall and work full-time at big pharmaceutical companies. Children's counts those as wins......»»

Category: topSource: bizjournals13 hr. 14 min. ago

Novartis Announces Positive Data on CAR-T Therapy, Kymriah

Zacks.....»»

Category: topSource: redinewsJun 18th, 2018

Ziopharm says FDA placed clinical hold on trial of CD19-targeted CAR T therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 18th, 2018

Gene-Editing Selloff Is Overdone

The science-journal studies that ignited a rout in Crispr Therapeutics, Editas Medicine, and other gene-therapy shares look to have been misunderstood......»»

Category: topSource: barronsJun 16th, 2018

A Cancer Blockbuster Gets Approved in China. Will the Floodgates Now Open?

Chinese drug regulators gave the nod to Bristol-Myers Squibb’s immune therapy star Opdivo. Dozens of companies are hoping they’re next. Bristol-Myers Squ.....»»

Category: europeSource: fortuneJun 15th, 2018

Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive

Your Daily Pharma Scoop: Wright Receives PMA, Allergan And Corbus Report Positive.....»»

Category: topSource: seekingalphaJun 15th, 2018

With suicide rates on rise, can therapy apps like Talkspace, BetterHelp help?

Millions of Americans have turned to mobile-device apps that offer therapy. But experts question whether these a.....»»

Category: topSource: usatodayJun 15th, 2018

How a Gaithersburg company is saving lives with bacteria-killing viruses

The Gaithersburg-based company is raising $5 million, ahead of a planned Series A round of at least $30 million in the first quarter of 2019, to bring a therapy for drug-resistant bacteria to market as soon as possible......»»

Category: topSource: bizjournalsJun 15th, 2018